WO2000043001A1 - Agents anti-inflammatoires - Google Patents

Agents anti-inflammatoires Download PDF

Info

Publication number
WO2000043001A1
WO2000043001A1 PCT/GB2000/000162 GB0000162W WO0043001A1 WO 2000043001 A1 WO2000043001 A1 WO 2000043001A1 GB 0000162 W GB0000162 W GB 0000162W WO 0043001 A1 WO0043001 A1 WO 0043001A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
group
alkenyl
substituted
Prior art date
Application number
PCT/GB2000/000162
Other languages
English (en)
Inventor
Andrew Paul Ayscough
Mark Whittaker
Original Assignee
British Biotech Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharmaceuticals Limited filed Critical British Biotech Pharmaceuticals Limited
Priority to EP00900731A priority Critical patent/EP1146868A1/fr
Priority to AU30655/00A priority patent/AU3065500A/en
Priority to JP2000594458A priority patent/JP2002535272A/ja
Publication of WO2000043001A1 publication Critical patent/WO2000043001A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Cette invention concerne des composés représentés par la formule (I) dans laquelle R4 est un ester ou un groupe thioester, et R, R1, R2 et R3 sont conformes à la spécification du descriptif. Ces composés inhibent l'activité hydrolase leukotriène-A4 intracellulaire et ont une action anti-inflammatoire.
PCT/GB2000/000162 1999-01-23 2000-01-21 Agents anti-inflammatoires WO2000043001A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00900731A EP1146868A1 (fr) 1999-01-23 2000-01-21 Agents anti-inflammatoires
AU30655/00A AU3065500A (en) 1999-01-23 2000-01-21 Anti-inflammatory agents
JP2000594458A JP2002535272A (ja) 1999-01-23 2000-01-21 抗炎症剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9901444.1 1999-01-23
GBGB9901444.1A GB9901444D0 (en) 1999-01-23 1999-01-23 Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
WO2000043001A1 true WO2000043001A1 (fr) 2000-07-27

Family

ID=10846359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000162 WO2000043001A1 (fr) 1999-01-23 2000-01-21 Agents anti-inflammatoires

Country Status (5)

Country Link
EP (1) EP1146868A1 (fr)
JP (1) JP2002535272A (fr)
AU (1) AU3065500A (fr)
GB (1) GB9901444D0 (fr)
WO (1) WO2000043001A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
FR3098217A1 (fr) * 2019-07-05 2021-01-08 Pharmaleads N-Formylhydroxylamines en tant qu’inhibiteurs mixtes de l’aminopeptidase N (APN) et de la néprilysine (NEP)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082088A1 (fr) * 1981-12-16 1983-06-22 Bernard Roques Nouveaux dérivés d'aminoacides, et leur application thérapeutique
WO1994010990A1 (fr) * 1992-11-13 1994-05-26 British Biotech Pharmaceuticals Limited Inhibition de la production du facteur de necrose tumorale
WO1995019965A1 (fr) * 1994-01-21 1995-07-27 Glycomed Incorporated Inhibiteurs synthetiques de metalloproteases matricielles et utilisations correspondantes
WO1995022966A1 (fr) * 1994-02-25 1995-08-31 Sanofi Winthrop, Inc. Derives de l'acide hydroxamique et de l'acide carboxylique, leur mode de preparation et d'utilisation
WO1999040910A1 (fr) * 1998-02-12 1999-08-19 British Biotech Pharmaceuticals Limited Agents anti-inflammatoires
WO1999041232A1 (fr) * 1998-02-13 1999-08-19 British Biotech Pharmaceuticals Limited Agents cytostatiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082088A1 (fr) * 1981-12-16 1983-06-22 Bernard Roques Nouveaux dérivés d'aminoacides, et leur application thérapeutique
WO1994010990A1 (fr) * 1992-11-13 1994-05-26 British Biotech Pharmaceuticals Limited Inhibition de la production du facteur de necrose tumorale
WO1995019965A1 (fr) * 1994-01-21 1995-07-27 Glycomed Incorporated Inhibiteurs synthetiques de metalloproteases matricielles et utilisations correspondantes
WO1995022966A1 (fr) * 1994-02-25 1995-08-31 Sanofi Winthrop, Inc. Derives de l'acide hydroxamique et de l'acide carboxylique, leur mode de preparation et d'utilisation
WO1999040910A1 (fr) * 1998-02-12 1999-08-19 British Biotech Pharmaceuticals Limited Agents anti-inflammatoires
WO1999041232A1 (fr) * 1998-02-13 1999-08-19 British Biotech Pharmaceuticals Limited Agents cytostatiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOURNIE-ZALUSKI M -C ET AL: "NEW BIDENTASES AS FULL INHIBITORS OF ENKEPHALIN-DEGRADING ENZYMES: SYNTHESIS AND ANALGESIS PROPERTIES", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 28, no. 9, 1 January 1985 (1985-01-01), pages 1158 - 1169, XP002019770, ISSN: 0022-2623 *
PENNING ET AL: "Kelatorphan and related analogs: potent and selective inhibitors of leukotriene A4 hydrolase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 5, no. 21, 1995, pages 2517 - 2522, XP002103716, ISSN: 0960-894X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
FR3098217A1 (fr) * 2019-07-05 2021-01-08 Pharmaleads N-Formylhydroxylamines en tant qu’inhibiteurs mixtes de l’aminopeptidase N (APN) et de la néprilysine (NEP)
WO2021005294A1 (fr) * 2019-07-05 2021-01-14 Pharmaleads N-formylhydroxylamines en tant qu'inhibiteurs de la neprilysine (nep), en particulier en tant qu'inhibiteurs mixtes de l'aminopeptidase n (apn) et de la neprilysine (nep)

Also Published As

Publication number Publication date
AU3065500A (en) 2000-08-07
GB9901444D0 (en) 1999-03-10
JP2002535272A (ja) 2002-10-22
EP1146868A1 (fr) 2001-10-24

Similar Documents

Publication Publication Date Title
KR100600518B1 (ko) 항균제
US6790834B1 (en) Cytostatic agents
EP1146868A1 (fr) Agents anti-inflammatoires
US6495597B1 (en) Cytostatic agents
EP1140058B1 (fr) Derives d'hydroxylamine n-formyle utilises comme agents antibacteriens
US6462023B1 (en) Cytostatic agents
US6306881B1 (en) Anti-inflammatory agents
AU718890C (en) Cytostatic hydroxamic acid derivatives
RU2246941C2 (ru) Антибактериальные агенты
IL137774A (en) Cytostatic substances
AU3266099A (en) Inflammatory cell inhibitors
KR20000044039A (ko) 세포 증식 억제성 히드록삼산 유도체
MXPA00007709A (en) Antibacterial agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG SK TR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000900731

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 594458

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09889770

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000900731

Country of ref document: EP

CR1 Correction of entry in section i

Free format text: PAT. BUL. 22/2002 UNDER (51) DELETE "A61B 6/370"

WWW Wipo information: withdrawn in national office

Ref document number: 2000900731

Country of ref document: EP